The Valley Desk

Clinical trial reportThe Lancet. OncologyPublished

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

13 of 32 authors shown in byline order.

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
The Lancet. Oncology
Published
Subject terms
Humans; Multiple Myeloma; Thalidomide; Dexamethasone; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Drug Resistance, Neoplasm; Adult; Aged; Middle Aged; Female; Male
PubMed ID
41519141
Added to directory
Source checked

Report a correction or request removal